Business
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE,
About this update from Nuvalent, Inc.
[{"type":"text","content":"Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies \nCAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors.\n\n \n \n \n \n \n \n\n \n\"I am excited to join the Nuvalent Board of Directors and have been impressed by both the team's capital efficient advancement of its two lead programs towards potential clinical proof of concept and the strong potential to deliver meaningful value to patients,\" said Ms. Protopapas. \"The Nuvalent team has demonstrated that it can combine drug discovery expertise with a deep understanding of medical needs to advance molecules that are differentiated in meaningful ways for the potential benefit of patients. I anticipate the portfolio will continue to grow and mature, and look forward to working with the team towards the goal of building a sustainable organization that can repeatedly discover, develop, and deliver meaningful new therapies for patients with cancer.\"\nMs. Protopapas joined Mersana in March 2015 and has a substantial track record of executive leadership and business growth in the field of oncology. Her broad industry experience ranges from global development to commercial expertise with a focus on building companies from start-ups to leaders in their categories. She will assume the role of Board Chair from Cameron Wheeler, Ph.D., Partner at Deerfield Management, who will remain on Nuvalent's Board of Directors.\n\"I am proud to have worked closely with this talented team to accelerate the formation and early growth of Nuvalent, and to help drive its successful evolution into a public company,\" said Dr. Wheeler. \"With continued confidence in Nuvalent's approach and long-term vision, we welcome Anna as incoming Board Chair to further strengthen the team as we navigate the next phase of Nuvalent's growth.\"\nNuvalent is currently enrolling patients in the Phase 1 portion of its ARROS-1 study, a Phase 1/2 clinical trial evaluating its lead candidate NVL-520, a ROS1-selective inhibitor, in pat...